Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

NCT07471815 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Triple Negative Breast Cancer

Interventions

DRUG: Camrelizumab + Risedronate Sodium + Chemotherapy

Sponsor

Harbin Medical University